News

Video

Tissue and Plasma-Based Mechanisms of Resistance to First-Line Osimertinib in EGFR-Mutant NSCLC: A Multi-Institutional Cohort

Related Videos
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Related Content
David R. Oveisi, MD
November 20th 2024

Expanded Indications for CAR T-Cell Therapies Shepard in New Era of Myeloma Care

D. Ross Camidge, MD, PhD; Rahul Gosain, MD, MBA, medical director, Wilmot Cancer Institute at Webster, director, Wilmot Cancer Institute Regional Infusion services, assistant professor, clinical medicine, Department of Medicine, Hematology/Oncology, University of Rochester
November 20th 2024

How the Drive to Connect the Oncology Community Built an Educational Podcast Platform: With D. Ross Camidge, MD, PhD; and Rahul Gosain, MD, MBA

Zorifertinib for EGFR+ NSCLC With CNS Metastases | Image Credit: © Cornflakesei - stock.adobe.com
November 20th 2024

Zorifertinib Receives NMPA Approval for EGFR+ NSCLC With CNS Metastases

Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB, head, Division of Radiotherapy and Imaging, The Institute of Cancer Research; fellow, the Royal College of Physicians, the Royal College of Radiologists
November 18th 2024

HPV16-Targeted Immunotherapy Is Set to Personalize HNSCC Management: With Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB

Parth A. Desai, MBBS, MD
November 20th 2024

Fox Chase Cancer Center Researcher Find New Treatment Targets in Microenvironment of Small Cell Lung Cancer

Maurie Markman, MD, president, Medicine & Science, City of Hope Atlanta, Chicago, and Phoenix
November 20th 2024

Cancer Clinical Trials: A Relevant Need to Clearly Define the Value to Individual Patients